MD Anderson, Flagship startup partner to design and test cancer drugs made with generative AI
Generate Biomedicines, a startup founded by the life science investment company Flagship Pioneering, has partnered with the University of Texas MD Anderson Cancer Center to develop protein therapies made from generative AI, the artificial intelligence technique that’s sweeping the web with text generators such as ChatGPT and image generators like DALL-E.
The collaboration, announced Thursday morning, will span the gamut of drug discovery and development. The pair will initially identify up to five targets in advanced cancers, including lung cancer, to design drugs for Generate’s computational and wet labs in Somerville, MA.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters